Simulations Plus, Inc., a leader in cheminformatics and biosimulation solutions for the biopharma industry, has announced the release of ADMET Predictor® 13, their advanced machine learning modeling platform. This latest version enhances functionality and AI/ML capabilities, promising faster, more precise predictions in drug discovery. The platform's advancements focus on three main areas: enhanced high-throughput PBPK simulations for improved decision-making, an expanded suite of ADMET models for heightened predictive accuracy, and enterprise-ready automation features to support data-centric R&D teams. These innovations aim to streamline drug design, optimization, and selection processes, reinforcing Simulations Plus's commitment to scientific rigor and efficiency in pharmaceutical research.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.